How should persistent facial tics be managed in a 12‑year‑old with Tourette’s syndrome after discontinuing escitalopram (Lexapro) and atomoxetine (Strattera)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Persistent Facial Tics in Tourette's Syndrome After Medication Discontinuation

For this 12-year-old with persistent facial tics after stopping Lexapro and Strattera, initiate behavioral therapy first (Comprehensive Behavioral Intervention for Tics), and if pharmacologic treatment is needed, start with an alpha-agonist (guanfacine or clonidine) as first-line therapy, followed by atomoxetine as an excellent alternative that can address both tics and any residual ADHD symptoms.

Understanding the Clinical Context

The discontinuation of both escitalopram and atomoxetine was appropriate, as the FDA label data confirms that Strattera (atomoxetine) does not worsen tics in patients with Tourette's disorder 1. The persistence of facial tics after stopping these medications indicates the tics are part of the underlying Tourette's syndrome rather than medication-induced, which is critical for treatment planning.

Tourette syndrome affects approximately 1 per 1,000 male children and commonly presents with neurobehavioral comorbidities including ADHD (50-75%) and obsessive-compulsive behaviors (30-60%) 2. The fact that this patient was on Strattera suggests possible comorbid ADHD, which must be considered in the treatment approach.

Treatment Algorithm

Step 1: Behavioral Therapy as First-Line Treatment

  • Comprehensive Behavioral Intervention for Tics (CBIT) should be the initial approach for persistent tic disorders 3
  • This is generally considered first-line treatment before pharmacotherapy
  • Behavioral therapy can be effective as monotherapy for many patients with troublesome tics

Step 2: Pharmacologic Treatment When Needed

If behavioral therapy is insufficient, inaccessible, or tics cause significant psychological, functional, or physical impairment:

First-Line Pharmacologic Options:

Alpha-agonists (preferred initial choice):

  • Guanfacine or clonidine are recommended as first-line pharmacologic agents 4, 5, 6, 7
  • These have Level A evidence for treating TS with comorbid ADHD 6
  • Particularly beneficial if any hyperactivity symptoms are present 7
  • Lower risk profile compared to antipsychotics
  • Can address both tics and ADHD symptoms simultaneously

Atomoxetine (excellent alternative):

  • Atomoxetine is specifically noted as "an excellent option to treat ADHD and tics" 5
  • Clinical trials demonstrated that atomoxetine does not worsen tics in patients with Tourette's disorder 1
  • Can be considered as first-line treatment in tic disorders 8
  • Particularly appropriate given this patient's history of Strattera use (suggesting possible ADHD comorbidity)
  • Non-controlled substance with around-the-clock effects

Second-Line Options (if first-line inadequate):

Atypical antipsychotics:

  • Risperidone has the best evidence level among atypical antipsychotics 9
  • Aripiprazole has FDA approval for TS and promising data with lower adverse reaction risk 9, 10
  • Tiapride (in Europe) has largest clinical experience with low adverse reaction rates 9

Typical antipsychotics (third-line):

  • Pimozide has best evidence among typical antipsychotics and showed superiority over haloperidol in efficacy and side effects 2
  • Haloperidol is FDA-approved but has more side effects 2

Critical Clinical Considerations

Avoid Iatrogenic Harm

The literature emphasizes that "the major morbidity of habit cough is iatrogenic, resulting from misdiagnosis and excessive treatment" in children 2. This principle applies to tic management—avoid overly aggressive treatment that may cause more harm than the tics themselves.

Assess Functional Impairment

Pharmacologic intervention should only be pursued when tics cause:

  • Psychological impairment (embarrassment, social isolation)
  • Functional impairment (academic performance, daily activities)
  • Physical impairment (pain, injury)

Monitor for Comorbidities

Given the high prevalence of ADHD (50-75%) and OCD (30-60%) in Tourette's syndrome 2, evaluate whether:

  • ADHD symptoms persist after Strattera discontinuation
  • Obsessive-compulsive symptoms are present
  • Anxiety or mood symptoms require attention

Medication Selection Strategy

If ADHD symptoms are prominent:

  • Alpha-agonists (clonidine/guanfacine) can address both conditions 6
  • Atomoxetine is an excellent choice for combined tic and ADHD management 5, 11
  • Stimulants are NOT contraindicated—recent evidence shows they are highly effective in ADHD with comorbid tics and do not worsen tics in the majority of patients 4

If tics are the primary concern:

  • Start with alpha-agonists (guanfacine preferred for once-daily dosing and better tolerability)
  • Consider risperidone if alpha-agonists fail 9

Common Pitfalls to Avoid

  1. Don't assume medications caused the tics: The FDA label confirms atomoxetine doesn't worsen tics 1
  2. Don't rush to antipsychotics: Alpha-agonists and atomoxetine should be tried first due to better safety profiles
  3. Don't avoid stimulants if ADHD is present: Evidence supports their use even with comorbid tics 4
  4. Don't treat without assessing impairment: Not all tics require pharmacologic intervention
  5. Don't forget behavioral therapy: CBIT should be offered before or alongside medication 3

Practical Implementation

Start with:

  • Guanfacine: Begin low (0.5-1 mg) and titrate slowly
  • OR Clonidine: 0.05 mg and increase gradually (note: may cause more sedation)
  • OR Atomoxetine: 0.5 mg/kg/day initially, target 1.2 mg/kg/day 1

Monitor closely for:

  • Tic frequency and severity (use standardized scales like YGTSS)
  • Sedation, blood pressure changes (with alpha-agonists)
  • Mood changes, appetite effects (with atomoxetine)
  • Functional improvement in school and social settings

Adjust treatment if:

  • No improvement after 4-8 weeks at therapeutic doses
  • Intolerable side effects emerge
  • Comorbid symptoms become more problematic than tics

References

Research

Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020

Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Research

Tourette Syndrome and comorbid ADHD: current pharmacological treatment options.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2013

Research

Tourette's Syndrome in Children.

Current treatment options in neurology, 2003

Research

Pharmacotherapy for Tourette Syndrome.

The Psychiatric clinics of North America, 2025

Research

Treatment of Tourette syndrome.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014

Related Questions

In a child with a tic disorder (Tourette syndrome) and ADHD who has not improved on guanfacine, what are the recommended next treatment options?
What is the best first-line pharmacologic treatment for a patient with ADHD and mild trichotillomania?
What are the medications for treating tics (involuntary muscle contractions)?
Is Adderall (amphetamine and dextroamphetamine) prescribed for Tourette's syndrome?
What medication options are appropriate for a patient with tics or Tourette syndrome who is already taking guanfacine extended‑release 1 mg daily, bupropion extended‑release 150 mg daily, and escitalopram 30 mg daily?
At what hemoglobin level can primaquine be initiated in a patient with normal glucose‑6‑phosphate dehydrogenase (G6PD) activity?
Is migraine a contraindication for deep transcranial magnetic stimulation (deep TMS)?
Is the provided impression and management plan appropriate for a 32-year-old female presenting for an annual physical with acute viral upper respiratory infection (dry cough, sinus congestion, headache), anxiety refractory to fluoxetine, heavy menstrual bleeding with irregular cycles and new facial/neck hirsutism, and obesity (BMI 30.1)?
Which antihistamines should be avoided in patients with arrhythmia, including those with congenital long‑QT syndrome or on other QT‑prolonging drugs?
Is sertraline 50 mg safe for blood pressure and does it cause hypotension?
What are the typical initial presenting symptoms of Tourette syndrome in children, including early motor and vocal tics?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.